Menstrual Suppression Is a Valuable Component of HSCT Care for Premenopausal Women
Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant.
Related Articles
Mobocertinib Will No Longer Be Available in US for EGFR Exon 20 Insertion+ NSCLC
Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.
Subgroup Analysis Shows Pembrolizumab Improves Outcomes in Clear Cell RCC
Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.
Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell…
Delayed HRQOL Outcomes Are Observed With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to…
Single-Fraction SABR Yields Comparable Overall Survival to Multi-Fraction SABR for Patients With Lung Oligometastases
Among patients with lung oligometastases, no significant differences in overall or disease-free survival were observed with single- and multi-fraction stereotactic ablative body radiotherapy.
Opinion: The Iris App Could Be a “Game-Changer” for Patients With Cancer
Iris app aims to leverage accessible technology to deliver supportive care to all patients with cancer.
Dose-Dense and Dose-Intense ABVD Is Linked To Improved PFS in Frontline Treatment of Advanced Classical Hodgkin Lymphoma
Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or…
Lutetium Lu 177 Vipivotide Tetraxetan Generates Enhanced Antitumor Activity in Patients With mCRPC
Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.
Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell…
Novel CAR T-Cell Therapy Shows Phase 1 Efficacy in Patients With mCRPC
A prostate stem cell antigen-directed CAR T-cell therapy agent showed preliminary efficacy in patients with metastatic castration-resistant prostate cancer.